NCT03034772View on ClinicalTrials.gov

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

February 8, 2019

Study Completion Date

July 5, 2019

Conditions

Neovascular Age-related Macular DegenerationWet Macular Degeneration

Interventions

DRUG

Dorzolamide-timolol

Topical eye drop (active comparator) used twice daily for study duration

OTHER

Artificial tears

Topical eye drop (placebo comparator) used twice daily for study duration

Trial Locations (5)

19107

Mid Atlantic Retina- Wills Eye Institute, Philadelphia

48073

Associated Retinal Consultants, Royal Oak

77030

Retina Consultants of Houston, Houston

94301

Palo Alto Medical Foundation, Palo Alto

02114

Ophthalmic Consultants of Boston, Boston

All Listed Sponsors

collaborator

Mid Atlantic Retina

OTHER

lead

Wills Eye

OTHER

NCT03034772 - Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter